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Abstract: PURPOSE Complementary and alternative medicine (CAM) use increases in cancer patients,
including adult patients with diffuse gliomas. METHODS Questionnaires addressing CAM use were
distributed to adult patients with gliomas of WHO grades II-IV and ECOG performance score of 0-2
during hospital visits and filled in anonymously. The study was conducted in nine centers in France from
May 2017 to May 2018. Descriptive cohort analyses and comparative analyses according to gender, age,
WHO grade, and recurrent versus newly diagnosed disease were conducted. RESULTS Two hundred
twenty-seven questionnaires were collected; 135 patients (59%) were male. Median age was 48 years,
105 patients (46%) declared having glioblastoma, 99 patients (43%) declared having recurrent disease.
Hundred-three patients (45%) had modified their alimentary habits after the glioma diagnosis. At the
time of the questionnaire, 100 patients (44%) were on complementary treatment, mainly vitamins and
food supplements, and 73 patients (32%) used alternative medicine approaches, mainly magnetism and
acupuncture. In total, 154 patients (68%) declared using at least one of these approaches. Expenditures
exceeding 100 € per month were reported by users in 14% for modification of alimentary habits, in 25%
for complementary treatment, and in 18% for alternative medicines. All approaches were commonly
considered as improving quality of life and experienced as efficient, notably those associated with more
expenditures. CONCLUSIONS CAM are frequently used by glioma patients in France. Underlying
needs and expectations, as well as potential interactions with tumor-specific treatments, and financial
and quality of life burden, should be discussed with patients and caregivers.
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Abstract: Purpose: Complementary and alternative medicine (CAM) use increases in cancer
patients, including adult patients with diffuse gliomas.
Methods: Questionnaires addressing CAM use were distributed to adult patients with
gliomas of WHO grades II-IV and ECOG performance score of 0-2 during hospital
visits and filled in anonymously. The study was conducted in nine centers in France
from May 2017 to May 2018. Descriptive cohort analyses and comparative analyses
according to gender, age, WHO grade, and recurrent versus newly diagnosed disease
were conducted.
Results: Two hundred twenty-seven questionnaires were collected; 135 patients (59%)
were male. Median age was 48 years, 105 patients (46%) declared having
glioblastoma, 99 patients (43%) declared having recurrent disease. Hundred-three
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patients (45%) had modified their alimentary habits after the glioma diagnosis. At the
time of the questionnaire, 100 patients (44%) were on complementary treatment,
mainly vitamins and food supplements, and 73 patients (32%) used alternative
medicine approaches, mainly magnetism and acupuncture. In total, 154 patients (68%)
declared using at least one of these approaches. Expenditures exceeding 100 € per
month were reported by users in 14% for modification of alimentary habits, in 25% for
complementary treatment, and in 18% for alternative medicines. All approaches were
commonly considered as improving quality of life and experienced as efficient, notably
those associated with more expenditures.
Conclusions: CAM are frequently used by glioma patients in France. Underlying needs
and expectations, as well as potential interactions with tumor-specific treatments, and
financial and quality of life burden, should be discussed with patients and caregivers.
Powered by Editor ial Manager®  and ProduXion Manager®  from  Aries System s Corporat ion
RESPONSE TO REFEREES 
 
Reviewer #1: The present study addresses the use of alternative medicine in glioma patients. 
Although several studies addressed the particular topic before, this the first to specifically address 
patients in France. Although certainly interesting and import the study would profit from some 
improvement. In the discussion the authors should put their data a little bit more into context with the 
previous studies addressing the same issue in other European countries - what is different and 
potentially special to the French population. 
 
RESPONSE 
We have inserted some considerations on the specificities of France (page 10 and page 11, in the 
"Discussion" paragraph. 
 
Some further points: 
 
COMMENT 
Is it possible to include the time since diagnosis? 
 
RESPONSE 
These data have been added (see page 6, in the "Patient characteristics" paragraph and in table 1). 
 
COMMENT 
A translated version of the entire questionnaire should be given in the supplementary material. 
 
RESPONSE 
This is what Supplementary Table 1 shows. May be this was overlooked. 
 
COMMENT 
Introduction: Gliomas represent the main primary brain tumors in adults. 
- what do you mean by "main"? The most frequent? 
 
RESPONSE 
This has been corrected in the text, page 4. 
 
COMMENT 
Was there a minimum of required fields to be addressed so the questionnaire was included in the 
analysis? Information should be provided on how many participants did not answer particular field. 




The questionnaires were distributed to patients that were volunteers to fill it anonymously. All 
questionnaires were taken into account and included in the analyses; 219 participants answered 
regarding smoking and alcohol habits, alimentation and diet, 224 participants regarding 
complementary treatment use, and 217 regarding alternative treatment use. This has been more 








We agree with this comment. This is unlikely to be correct, but illustrates the limitations of a 
questionnaire. We have specifically commented on this (see page 13, in the "Discussion" paragraph). 
 
COMMENT 
Which patients were addressed? Is there a potential inclusion bias? 
 
RESPONSE 
Response to Reviewer Comments
The questionnaire was distributed to all glioma patients seen from May 2017 to May 2018, with an 
ECOG performance score of 0-2, as stated in the Methods section (Methods, page 5). Inclusion 
criteria were provided to all centers and investigators. The answers provided here correspond to 
declaration of participants only. Please see comment in the limitations section (page 13). 
 
COMMENT 
How many received information on complementary therapy from oncologist? 
 
RESPONSE 
This information is given in Tables 3 to 5 (13% among participants who have declared a modification 
of alimentary habits or being under diet; 15% among patients who have declared complementary 
treatment consumption and 7% among patients who have declared alternative treatment use). 
 
COMMENT 
figure displaying the rated impact and efficacy of the used methods is enough - would omit the 
description of Figure 1 in the text 
- Figure 1 - what is the y axis? % of patients? 
- Total number of patients included in the particular analysis should be given 
 
RESPONSE 
We apologize for omitting the legend for the Y-axis – the referee is correct (this has been fixed). Total 
number of patients included are now provided in the figure legend. The figure is described only with 
one sentence each for panels A/B, C/D and E/F. The percentages of patients have been modified for 
clarity and take into account now only patients who declared CAM use. 
 
COMMENT 
Correlation of impact on quality of life/ efficacy and cost should be described also giving numbers - 
correlation coefficient - page 8 2nd paragraph 
 
RESPONSE 
We feel that we should not apply too complicated statistics here since these are entirely explorative 
considerations without a predefined analysis plan and since we have only small subgroups of patients 
(0-30) in each category. As proposed elsewhere, we have reduced the numbers in the text. 
 
COMMENT 
Where there patients with multiple CAM use? Alternative treatment in addition to food changes? 
 
RESPONSE 
We thank the reviewer for this interesting point. We have added this information (see pages 6-7, in the 
"Pattern of CAM use" paragraph). 
 
COMMENT 
What is diagnosis "other"? 
 
RESPONSE 
Other refers to other brain tumors according to the patients. Patients declared having a 
medulloblastoma (n=3), meningioma (n=1), hemangiopericytoma (n=1), hemangioblastoma (n=1), or 
meningioma/schwannoma in the context of neurofibromatosis (n=1). This has been clarified as a 
footnote to Table 1. 
 
COMMENT 
Did all patients indicating to used CAM also indicate the efficacy and impact on quality of life? 
 
RESPONSE 
This has been clarified in the tables. For clarity, only patients that declared CAM use have been now 




Consider to shorten the results and to not repeat too many numbers also given in the tables. 
 
RESPONSE 
The results have been condensed. 
 
COMMENT 
Consider to shorten the discussion 
 
RESPONSE 
The discussion has been condensed. 
 
COMMENT 
No numbers should be given in the discussion 
 
RESPONSE 
This has been revised. 
 
COMMENT 
Data on the association of Glioma grade and CAM use should be included in the main document - was 
is association also explored in the previous studies or is this a new finding? Why are GBM patients 
more interested in CAM? 
 
RESPONSE 
These data have been shifted to the main text. We have also expressed our interpretation that 
glioblastoma patients are more desperate and therefore more likely to seek alternative treatment 
options (see page 10, in the "Discussion" paragraph). 
 
COMMENT 
Page 10 line 34 to 41 - consider to make 2 sentences 
 
RESPONSE 
This has been done. 
 
COMMENT 
Which data supports the safety of CAM especially in combination with treatment in glioma patients - is 
there a study supporting this notion on page 11 line 32 
 
RESPONSE 
This is an (our) assumption, but this was never formally tested. We modified the text accordingly (page 
12, in the "Discussion" paragraph). 
 
 
Reviewer #3: This is an interesting study on the use of complementary and alternative medicine use in 
glioma patients in France. 
It is a retrospective study using surveys with its known limitations, but for the rest the study is well-
performed and well-written. 
 
I have some comments. 
 
COMMENT 
1. Did the patients experience negative effects of the CAM? And did the authors ask also whether 
CAM had a negative impact on quality of life? 
 
RESPONSE 
The questionnaire was as shown in Table S1. The participants could indicate on a scale from 1 (bad) 




2. There was a high no-response rate for impact on quality of life, efficacy and estimation of cost per 
month (59-68%). Can the others explain this high no response rate? 
What is the impact of this high no response rate on the interpretation of the data? Do the authors think 
that these patients that experience a low quality of life or no efficacy did not respond. Please discuss. 
 
RESPONSE 
We are thankful for this comment because it made clear that our data presentation was not clear 
enough. Percentages now are exactly explained and “no response” figures are given in Tables 3-5. 
Regarding the “no “response” rates that remain, we prefer not to speculate too much whether non-
responders had less favorable experiences with CAM use. It can also not be excluded that some 
questions were too complicated for some patients. We have included considerations on this topic (see 
page 13, in the "Discussion" paragraph). 
 
COMMENT 
3. page 35: cost or reimbursement was less important in the decision making in Germany and 
Switzerland. Compared to which other countries? 
 
RESPONSE 
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Purpose: Complementary and alternative medicine (CAM) use increases in cancer 
patients, including adult patients with diffuse gliomas. 
Methods: Questionnaires addressing CAM use were distributed to adult patients with 
gliomas of WHO grades II-IV and ECOG performance score of 0-2 during hospital 
visits and filled in anonymously. The study was conducted in nine centers in France 
from May 2017 to May 2018. Descriptive cohort analyses and comparative analyses 
according to gender, age, WHO grade, and recurrent versus newly diagnosed 
disease were conducted. 
Results: Two hundred twenty-seven questionnaires were collected; 135 patients 
(59%) were male. Median age was 48 years, 105 patients (46%) declared having 
glioblastoma, 99 patients (43%) declared having recurrent disease. Hundred-three 
patients (45%) had modified their alimentary habits after the glioma diagnosis. At the 
time of the questionnaire, 100 patients (44%) were on complementary treatment, 
mainly vitamins and food supplements, and 73 patients (32%) used alternative 
medicine approaches, mainly magnetism and acupuncture. In total, 154 patients 
(68%) declared using at least one of these approaches. Expenditures exceeding 100 
€ per month were reported by users in 14% for modification of alimentary habits, in 
25% for complementary treatment, and in 18% for alternative medicines. All 
approaches were commonly considered as improving quality of life and experienced 
as efficient, notably those associated with more expenditures.  
Conclusions: CAM are frequently used by glioma patients in France. Underlying 
needs and expectations, as well as potential interactions with tumor-specific 












































































Complementary and alternative medicine (CAM) is operationally defined as any 
practice that aims at cure or at obtaining similar effects as evidence-based medicine, 
but without scientific evidence and without clinical trial data to support efficacy and 
safety. Some approaches have been integrated into standards of care on a regional 
level, others have been explored in trials, some are toxic or violate local laws. 
However, CAM is frequently and probably increasingly used in cancer patients [1]. 
CAM is also sometimes denoted as complementary and alternative practices and 
products (CAPP), complementary and integrative medicine (CIM), complementary 
medicine (CM), complementary and traditional medicine or complementary health 
approaches (CHA). It can include pharmacological-like therapies, diets, modification 
of alimentation, food supplements, mind-body interventions, and others. No widely 
accepted consensual international definition of CAM is available, rendering 
comparisons across studies from different countries and periods difficult. By default, 
CAM represent approaches that are outside of the "mainstream medical model" [2]. 
The Cochrane group has defined CAM as " therapies used in treating or preventing 
disease" and has identified 70 different terms or combination of terms. Supplements 



































































medically diagnosed deficiency states and disorders, vitamins used for prevention of 
treatment effects, and exercise therapy are not considered as CAM [2]. 
Second to meningiomas gliomas represent the most common primary brain tumors in 
adults. Their prognosis varies by WHO grade and molecular subtype, available 
treatments, and the patients’ general and neurological condition. Glioblastoma, the 
most malignant subtype of glioma (WHO grade IV), accounts for 56.6% of all gliomas 
[3]. Median survival for patients with glioblastoma is in the range of 16 months in 
clinical studies [4-8], but remains at 12 months on a population level [9]. WHO grade 
II and III gliomas have a better prognosis with median survival times in clinical 
studies of up to 5 years for anaplastic gliomas without 1p19q codeletion and up to 14 
years in the presence of 1p19q codeletion [10-12], and up to 13 years for molecularly 
unselected "high risk" WHO grade II glioma [13]. In this context of severe illness and 
limited efficacy of evidence based-medicine, patients and relatives may more often 
resort to CAM.  
The present study was conducted to explore CAM use in adult glioma patients in 
France, to determine whether CAM use may affect quality of life, familial 
organization, leisure activities and to estimate the cost and the financial 
consequences of different CAM approaches, with the goal to better understand 









































































We conducted a prospective multi-center study in 9 French centers within the North 
East Neuro-Oncology (NENO) network. From May 2017 to May 2018 adult patients 
with histologically confirmed diffuse glioma of WHO grades II-IV and an ECOG 
performance score of 0-2 were asked to fill out a questionnaire anonymously at any 
time during the course of disease. The questionnaire was designed by ELR in 
cooperation with NS and approved by all participating sites. The questionnaires were 
distributed during hospital visits and completed during the same appointment. They 
included four different parts: (1) patient and tumor characteristics, including treatment 
received for the glioma, (2) modification of alimentation habits, (3) complementary 
treatments and (4) alternative medicine/traditional medicine use. An English version 
of the questionnaire is shown in Table S1. Patients were asked to grade the efficacy 
of such therapies and their impact on their own quality of life on a numerical analog 
scale from 1 (lowest) to 10 (highest). In addition, we interrogated source of 
information on CAM, perceived impact on quality of life, perceived efficacy, estimated 
cost per month (in €), and impact on familial life, leisure activities, and finances. All 
returned questionnaires were included in the analysis.  
Descriptive analyses of the population as well as comparative analyses according to 
gender, age, WHO grade (IV versus other WHO grades), and recurrent disease 
versus newly diagnosed setting were conducted using the Chi-square test. Only 
patients who declared using the respective CAM were included in the descriptive 
analyses of CAM consumption. 
A level of significance of 5% was used. Analyses were performed with SAS V9.4 and 









































































Two hundred twenty-seven anonymous questionnaires were filled in between May 
15, 2017 and May 31, 2018. Hundred thirty-five participants declared to be male 
(59%) and 79 patients declared to be female (35%). Median age was 48 years. The 
diagnoses were WHO grade II glioma in 29%, grade III glioma in 16% and 
glioblastoma (grade IV) in 46%. Beyond surgery, patients reported as first-line 
treatment radiotherapy alone in 5 cases (2%), chemotherapy alone in 131 cases 
(58%), and their combination in 31 cases (14%). Ninety-nine patients (43%) had 
experienced recurrence (Table S2). The median interval between diagnosis and 
questionnaire completion was declared to be 20 months. 
 
Patterns of CAM use 
Hundred-three patients (45%) declared having modified their alimentary habits, 100 
patients (44%) were on complementary treatment, and 73 patients (32%) used 
alternative medicine approaches; 154 patients (68%) declared using at least one of 
these approaches. Sixty-seven patients (29%) declared having changed their 
alimentation habits and taking complementary treatment, 46 patients (20%) declared 
having changed their alimentation habits and using alternative therapy, and 48 
patients (21%) declared using both complementary treatment and alternative 
therapy. Thirty-five patients (15%) used CAM from all three categories. 
Among patients who answered to the question, a modification of familial organization 



































































association with modification of alimentation and diets (Figure S1). An impact on 
leisure activities was reported by 8% to 17% of patients using CAM, and was mainly 
related to complementary treatment. Among patients who answered to the question, 
a financial impact was reported by 15% to 20% of patients, mostly reported by 
patients using complementary treatment (20%) and alternative therapies (17%). 
Glioblastoma patients as opposed to patients with other tumors used significantly 
more often at least one CAM approach. The difference was more prominent for 
modification of alimentary habits and use of complementary treatment than for use of 
alternative therapy. No association was found between gender, age, or recurrent 
disease and the use of one or these approaches (Table 1). 
 
Smoking and alcohol habits, alimentation and diet 
Thirty-five patients (15%) declared having modified their smoking habits since the 
diagnosis of the brain tumor, however, 57 patients (50%) reported ongoing 
consumption. Only 56 patients (25%) reported no current alcohol consumption. 
Hundred-three patients (45%) reported a modification of alimentary habits. More than 
25% of the patients reported an increase in the consumption of green tea, curcuma, 
or lemon, and 27 patients (12%) followed a diet, including a ketogenic diet in 5 
patients. Information on alimentation and diet was mainly received from relatives 
(26%), and less frequently from general practitioners (15%), oncologists (13%). 
The impact on quality of life of modified alimentation was estimated as good with a 
median of 7 on the scale from 1 (lowest) to 10 (highest). Thirty-eight patients (35%) 
rated the impact on quality of life at 4-7 and 35 patients (32%) at 8-10. Efficacy was 
also perceived as good, with a median of 7. Forty-two patients (39%) rated the 



































































alimentation habits was provided by 63 patients (58%); it was estimated as less than 
30 € per month by 35 patients (32%) and as more than 200 € per month by 10 
patients (9%). Twenty-two patients (20%) declared that modifications of alimentation 
and diet had an impact on their familial organization, 12 patients (11%) on their 
leisure activities, and 12 patients (11%) on their finances (Table 2). Expenditures 
exceeding 200 € per month were not necessarily perceived as having more impact 
on quality of life and as more efficacious than expenditures of 200 € or less per 
month (Figure 1A,B). 
 
Complementary treatment 
Hundred participants (44%) declared having taken or taking complementary 
treatments, mainly vitamins (23%), food supplement (22%), phytotherapy (15%) or 
homeopathy (15%). Information on complementary treatment was mainly received 
from relatives (30%) or general practitioners (29%). The impact on quality of life was 
judged as good and efficient, with a median of 7 each. Fifty-five patients (55%) rated 
the impact on quality of life at 4-7 and 32 patients (32%) at 8-10. Forty patients (40%) 
rated efficacy at 4-7 and 37 patients (37%) at 8-10.  
Information on cost of altered alimentation habits was provided by 84 patients (84%). 
Cost of less than 30 € per month was reported by 38 patients (38%) whereas 200 € 
or more per month were invested by 15 patients (15%). Seventeen patients (17%) 
declared that the complementary treatment had an impact on their familial 
organization, 16 patients (16%) on their leisure, and 18 patients (18%) on their 
finances (Table 3). No clear correlation was observed between cost and quality of life 





































































Use of alternative treatment was reported by 73 patients (32%). Twenty-two patients 
(30%) declared to use mainly magnetism, 16 acupuncture (22%), 15 sophrology 
(21%) and 12 energizing therapy (16%). Information on these techniques was given 
mainly by relatives (58%). Patients estimated that the impact of alternative treatment 
on quality of life was good and that these approaches were efficient with a median 
score of 8. Twenty patients (10%) rated the impact on quality of life at 4-7 and 38 
patients (19%) at 8-10. Twenty-three patients (31%) rated the efficacy at 4-7 and 38 
patients (52%) at 8-10. Information on cost was provided by 63 patients (86%). It was 
declared as below 30 € per month by 22 patients (30%) and as more than 200 € per 
month by 6 patients (8%). An impact on familial organization was declared by 12 
participants (16%), on leisure activities by 5 patients (7%) and on finances by 11 
patients (15%) (Table 4). Alternative therapies received high ratings for impact on 






There is increased awareness of CAM use in general oncology. In a meta-analysis 
on studies involving more than 65,000 cancer patients in 18 countries conducted until 
January 2009, heterogeneity was observed that may have partially been related to 
differences between surveys. CAM use was estimated at 40%, with a clear increase 
in use over time: 25% in the 1970s and 1980s, more than 32% in the 1990s, and 



































































survivors in 2007 [14]. In another study, 720 questionnaires were collected between 
2014 and 2016 in Germany. Here the rate of CAM use was 29% [15]. 
Specifically brain tumor patients may be interested in CAM because of perceived and 
factual shortcomings of available treatments. The present study is the first survey on 
CAM use by glioma patients conducted in France. It indicates widespread CAM use, 
with more than two thirds of participants declaring using at least one CAM approach. 
Information on CAM use was mainly received from family and friends (Tables 2-4). A 
positive impact on quality of life was commonly perceived, and efficacy was generally 
judged as good for all three CAM categories. A diagnosis of glioblastoma as opposed 
to lower WHO grade glioma was associated with more frequent CAM use, 
presumably because glioblastoma patients feel more need to fight their disease than 
patients with less malignant tumors (Table 1). 
Previous contemporary studies have explored CAM use in glioma patient cohorts in 
the US and Canada [16-18], Germany [19] and Switzerland [20]. CAM use was in the 
range of 24% to 77%, partially because of differences in the definition of CAM  [16-
21] (Table S3). In these other cohorts, information on CAM was also mainly received 
by relatives or via internet, and a positive effect was generally perceived by CAM 
users [16-21]. In contrast to other reports, no association of CAM use with younger 
age [16-21] or female gender [17,19] was noticed in our survey. One might speculate 
that age loses significance as internet use as an important source of information 
becomes more prevalent among older patients, too. In our study, the cost per month 
was usually less than 50 €, in other studies, it was usually also estimated at inferior 
to 50 € or between 50 and 100 € [16,18,19]. The median annual cost for CAM users 
increased from 120 $AU in 1993 to 228 $AU in 2000 in Australia, with a median 



































































The high consumption of CAM in the glioma patient population raises several 
important points, notable the impact on quality of life, its cost, the safety of agents, 
and potential interactions with cancer therapy. Most patients reported a positive 
impact of CAM use on quality of life. The impact on quality of life of CAM was 
previously evaluated using the Functional Assessment of Cancer Treatment–Brain 
(FACT–Br) questionnaire among 718 participants including 33% of CAM users [23]. 
The overall quality of life was not associated with CAM use, a lower emotional quality 
of life was associated with any CAM use and higher functional quality of life 
associated with body-oriented CAM use. Thus, objective evidence to support an 
impact of CAM on quality of life remains to be generated. 
The quality of products and their safety should be discussed with patients. Mercury, 
lead and arsenic were analyzed in 193 Ayurvedic medicines purchased between 
August and October 2015 on a Website. The frequency of detection of metal was 
20.7% among US-manufactured products versus 19.5% in products from India. Rasa 
shastra contained a greatest content of metals (p=0.007). Among products containing 
metal, 95% were available on US websites and 75% claimed "Good Manufacturing 
Practice" and all of them exceeded the acceptable standard for daily metal ingestion 
[24]. 
Few data are available on the toxicity of CAM. Most CAM are probably safe, 
however, minor but also major toxicities have been observed, such as 
hypersensitivity reactions, and neurological, cardiovascular, gastro-intestinal, renal 
and liver toxicities. Development of second cancer has also been linked to CAM use 
[25,26]. 
A possible interaction of the combination of conventional pharmacotherapy and 



































































[15], e.g., an induction of the cytochrome P450 enzyme system has been reported 
after using St. John's wort [27]. Accordingly, CAM use should be explored at the start 
of conventional pharmacotherapy to avoid pharmacokinetic or pharmacodynamic 
interactions. 
Ketogenic or calorically restricted diets reduced tumor growth in preclinical studies 
[28,29]. The ERGO trial explored the feasibility of the ketogenic diet in 20 patients 
with recurrent glioblastoma. Among them, 3 (15%) discontinued the diet because of 
poor tolerability, and no clinical activity was noted [30]. No association between 
glioblastoma outcome and multivitamins or omega-3 fatty acids was observed in an 
exploratory analysis among 470 patients, but vitamin D users had a reduced mortality 
whereas vitamin E users had a non-significantly higher mortality [21]. 
A poor communication regarding CAM between patients and physicians has been 
reported [31]. Up to 74% of patients with cancer or specifically glioma declared that 
physicians were not informed of CAM use [18,32,33]. From the patient's perspective, 
the main causes making the communication between CAM users and physicians 
difficult are the lack of interest or the opposition of physicians, the lack of scientific 
evidence reported by the physicians and an anticipated negative response from the 
physicians [31,34]. The main motivation of glioma patients to use CAM was to 
contribute actively to the treatment, but not to question standard treatments. Cost or 
reimbursement was not important in the decision making in Germany and 
Switzerland [19,20]. 
Limitations of the present study include the limited number of patients for subgroups, 
the bias introduced by patient preferences to respond to the questionnaire or not, the 
lack of longitudinal data, and the inherent limitations of a survey without the option to 



































































treatment is highly unlikely to be correct. Furthermore, no data on safety were 
collected although a survey would probably be not the adequate tool to collect such 
data [35]. Future studies should prospectively address to what extent CAM use 
exerts intrinsic toxicity or alters tolerability and safety of standard cancer therapies or 
novel agents administered in the context of clinical trials [15]. As a prerequisite for 
that, it would be important to implement proper CAM use documentation in clinical 
patient records [36]. 
We conclude that there is high prevalence of CAM use among adult glioma patients 
in France. These should be interrogated and discussed with patients and caregivers 
during the course of the disease to identify patient needs and preferences as well as 
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Figure 1. Perceived impact on quality of life and efficacy of CAM in glioma 
patients. The impact of various CAM categories (A,B alimentation and diet, C,D 
complementary treatment, E,F alternative treatment) was graded on a numeric 
analog scale from 0 to 10 (poor to good) and then grouped for graphic representation 
as 1-3, 4-7 or 8-10, and related to three levels of expenditures per month (less than 
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Glioma WHO grade 






















1 Comparative analysis according to gender (women, n=79 versus men, n=135), age (<35, n=51 
versus 34-45, n=53 versus 45-60, n=63 versus >60 years, n=57), gliomas WHO grade 
(glioblastoma, IV, n=105 versus other WHO grades, n=110), and recurrence experienced 
(recurrent disease, n=102 versus newly diagnosed setting, n=125) were conducted using Chi-
square test. A level of significance of 5% was used (significant differences in bold).





Table 2. Smoking, alcohol habits, alimentation and diet 
 n (%) or median 
(minimum-maximum) 
Smoking habits 
































modification of smoking habits since the diagnosis (% of participants) 
 
yes: 114 (50%)  
no:112 (49%) 
no response: 1 (1%) 
  
yes: 103 (90%)  
no: 7 (6%) 
no response: 4 (3%) 
 
yes: 5 (4%)  
no: 103 (90%) 
no response: 8 (7%) 
 
yes: 2 (1%)  
no: 106 (93%) 
no response: 6 (5%)  
 
yes: 57 (50%)  
no: 49 (43%) 
no response: 8 (7%) 
 
yes: 32 (14%)  
no: 151 (66%) 
no response: 44 (19%) 
 
yes: 11 (34%) 
no: 18 (56%) 
no response: 3 (9%) 
 
7 (6%)  
no:155 (68%) 
no response: 65 (29%) 
 
yes: 35 (15%) 
no: 100 (44%) 
no response: 92 (40%) 
Alcohol consumption (% of participants) 
no alcohol 
less than 2 glasses per day 
between 2 and 4 glasses per day 













change: 103 (45%) 
no change:116 (51%) 




- addition or omission of aliments (% of participants who declared a 
modification of alimentary habits, n=103)  
 
 
Addition of (among patients who declared a modification of 
alimentary habits, n=103) 













































change: 81 (79%) 
no change:15 (14.5%) 




yes: 31 (30%) 
no: 57 (55%) 
no response: 15 (14%) 
 
yes: 28 (27%) 
no: 60 (58%) 
no response: 15 (14%) 
 
yes: 27 (26%) 
no: 61 (59%) 
no response: 15 (14%) 
 
yes: 23 (22%) 
no: 64 (62%) 
no response: 16 (15%) 
 
yes: 22 (21%) 
no: 66 (64%) 
no response: 15 (14%) 
 
yes: 20 (19%) 
no: 68 (66%) 
no response: 15 (14%) 
 
yes: 20 (19%) 
no: 68 (66%) 
no response: 15 (14%) 
 
yes: 18 (17%) 
no: 70 (68%) 
no response: 15 (14%) 
 
yes: 18 (17%) 
no: 70 (68%) 
no response: 15 (14%) 
 
yes:16 (7%) 
no: 72 (70%) 
no response: 15 (14%) 
 
yes: 16 (7%) 
no: 72 (70%) 





















yes: 14 (13%) 
no: 74 (72%) 
no response: 15 (14%) 
 
yes: 11 (10%) 
no: 77 (74%) 
no response: 15 (14%) 
 
yes: 9 ((9%) 
no: 79 (77%) 
no response: 15 (14%) 
 
yes: 8 (7%) 
no: 80 (78%) 
no response: 15 (14%) 
 
yes: 56 (4%) 
no: 34 (33%) 
no response: 13 (13%) 
Diet 




















- other (% among participants under diet, n=27) 
 
yes: 27 (12%) 
no: 189 (83%) 
no response: 11 (5%) 
 
yes: 5 (18%) 
no: 16 (559%) 
no response: 6 (22%) 
 
yes: 4 (15%) 
no: 16 (59%) 
no response: 7 (26%) 
 
yes: 0 (0%) 
no: 20 (74%) 
no response: 7 (26%) 
 
yes: 0 (0%) 
no: 20 (74%) 
no response: 7 (26%) 
 
yes: 14 (52%) 
no: 6 (22%) 
no response: 7 (26%) 
Information on alimentation and diet received from 
(% among participants who declared a modification of alimentary 
habits or being under diet, n=108) 
- oncologist 
- general practitioner 
- pharmacist 
- nurse at hospital 



















Positive impact of modified alimentation on quality of life on a 
scale from 1 to 10 according to the patient (% among participants 
who have declared a modification of alimentary habits or being under 
diet, n=108) 














Efficacy of modified alimentation on a scale from 1 to 10 
according to the patient (% among participants who have declared 
a modification of alimentary habits or being under diet, n=108) 













Estimation of cost of modified alimentation per month (% among 
participants who declared a modification of alimentary habits or 


















Impact of modified alimentation on (% among participants who 
declared a modification of alimentary habits or being under diet, 
n=108) 












yes: 22 (20%) 
no: 55 (51%) 
no response: 31 (28%) 
 
yes: 12 (11%) 
no: 66 (61%) 
no response: 30 (28%) 
 
yes: 12 (11%) 
no: 66 (61%) 
no response: 30 (28%) 
 




Table 3. Complementary treatment 
 
Any complementary treatment supplement (% of participants) yes: 100 (44%) 
no: 124 (55%) 
no response: 3 (1%) 
Vitamins (% of participants) yes: 52 (23%)  
no: 172 (76%) 
no response: 3 (1%) 
Food supplement (% of participants) yes: 51 (22%)  
no=173 (76%) 
no response: 3 (1%) 
Phytotherapy (% of participants) yes: 35 (15%) 
no: 189 (83%) 
no response: 3 (1%) 
Homeopathy (% of participants) yes: 34 (15%) 
no: 190 (84%) 
no response: 3 (1%) 
Other medication without prescription (% of participants) yes: 21 (9%) 
no: 201 (89%) 
no response: 5 (2%) 
Information received from (% among patients who declared 
complementary treatment consumption, n=100)* 
- oncologist 
- general practitioner 
- pharmacist 
- nurse at hospital 
- nurse outside of hospital 
- relatives 














Positive impact on quality of life on a scale from 1 to 10 
according to the patient (% among patients who declared 
complementary treatment consumption, n=100)* 













Efficacy on a scale from 1 to 10 according to the patient (% 
among patients who declared complementary treatment 
consumption, n=100)* 













Estimation of the cost per month (% among patients who 



















Impact on (% among patients who declared complementary 
treatment consumption, n=100)* 











yes: 17 (17%) 
no: 75 (75%) 
no response: 8 (8%) 
 
yes: 16 (16%) 
no: 76 (76%) 
no response: 8 (8%) 
 
yes: 18 (18%) 
no: 74 (74%) 
no response: 8 (8%) 
 
 
*Only patients who declared a consumption of any complementary treatment were included in 
the calculation  
 
 8 
Table 4. Alternative treatment 
 
Any alternative medicine (% of participants) yes: 73 (32%) 
no: 144 (63%) 
no response: 10 (4%) 
Magnetism (% of participants who declared alternative treatment use) 22 (30%) 
Acupuncture (% of participants who declared alternative treatment 
use) 
16 (22%) 
Sophrology (% of participants who declared alternative treatment use) 15 (21%) 
Energizing therapy (% of participants who declared alternative 
treatment use) 
12 (16%) 
Aromatherapy (% of participants who declared alternative treatment 
use) 
8 (11%) 
Chiropractic (% of participants who declared alternative treatment use) 2 (3%) 
Ayurvedic medicine (% of participants who declared alternative 
treatment use) 
2 (3%) 
Hypnotherapy (% of participants who declared alternative treatment 
use) 
5 (7%) 
Auriculotherapy (% of participants who declared alternative treatment 
use) 
1 (1%) 
Other (% of participants who declared alternative treatment use) 21 (29%) 
Information received from (% of participants who declared 
alternative treatment use) 
- oncologist 
- general practitioner 
- pharmacist 
- nurse at hospital 
- nurse outside of hospital 
- relatives 














Positive impact on quality of life on a scale from 1 to 10 
according to the patient (% of participants who declared alternative 
treatment use) 













Efficacy on a scale from 1 to 10 according to the patient (% of 
participants who declared alternative treatment use) 












Estimation of the cost per month (% of participants who declared 



















Impact on (% of participants who declared alternative treatment use) 













yes: 12 (16%) 
no: 51 (70%) 
no response: 10 (14%) 
 
yes: 5 (7%) 
no: 58 (79%) 
no response: 10 (14%) 
 
yes: 11 (15%) 
no: 52 (71%) 
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